1 / 29

Introduction to Medicines Quality Assurance and Safety

Introduction to Medicines Quality Assurance and Safety. Technical Briefing Seminar, 29 October to 2 November 2012. Dr Lembit Rägo Coordinator Quality Assurance and Safety: Medicines Essential Medicines and Pharmacutical Policies World Health Organization Geneva, Switzerland

bsaffold
Download Presentation

Introduction to Medicines Quality Assurance and Safety

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Introduction to Medicines Quality Assurance and Safety Technical Briefing Seminar, 29 October to 2 November 2012 Dr Lembit Rägo Coordinator Quality Assurance and Safety: Medicines Essential Medicines and Pharmacutical Policies World Health Organization Geneva, Switzerland E-mail: ragol@who.int

  2. Why medicines are special category of products? • Consumers, patients and health care workers have limited capacity to judge there • SAFETY • QUALITY • EFFICACY

  3. Usual perceptions may not help in Making judgements about medicines … Taste Appearance Smell

  4. Are all medicines safe, effective and meet quality criteria? • No, they are not • Some are safe, but not effective or necessarily meet the quality criteria • Some may be effective, meet quality criteria but are not safe • Some meet quality criteria but are not necessarily safe or have any efficacy

  5. Quality - Safety • Some safety parameters are determined by quality • Some safety parameters are determined by the intrinsic properties of active pharmaceutical ingredient(s)

  6. What type of medicines we have? • Originator products • Multisource (generic) products • KEY – INTERCHANGEABILITY, more important THERAPEUTIC INTERCHNGEABILITY • ALL LITERATURE IS BASED ON ORGINATORS • No interchangeability – NEED FOR NEW SAFETY and EFFICACY DATA, NEW BOOKS HAVE TO BE WRITTEN • Other type of products • Biological products including vaccines and blood products • "Biosimilars" • Radiopharmaceuticals • Traditional medicines

  7. What type of regulations exist and how they differ? • For innovator products proof of QUALITY, SAFETY and EFFICACY is needed • For multisource products QUALITY, safety and efficacy data is referred to the originator providing only evidence about interchangeability (bioequivalence, clinical testing, in limited cases dissolution data)

  8. Regulations: Global vs National • National regulations still differ a lot • What is ICH and what it is not? • Regional harmonization initiatives • Do global norms exist for generics?

  9. In book: Drug Benefits and Risks, Chapter 6, 2008

  10. Main regulatory functions • Table 1. Principal medicines regulatory functions • Licensing of the manufacture, import, export, distribution, promotion and advertising of medicines • Assessing the safety, efficacy and quality of medicines, and issuing marketing authorization for individual products • Inspecting and surveillance of manufacturers, importers, wholesalers and dispensers of medicines • Controlling and monitoring the quality of medicines on the market • Controlling promotion and advertising of medicines • Monitoring safety of marketed medicines including collecting and analysing adverse reaction reports • Providing independent information on medicines to professionals and the public • Source: WHO Policy Perspectives on Medicines no 7, 2003.

  11. Is quality of medicines a problem? • Yes, a HUGE problem • - 2012 Pakistan case – 135 deaths • - Sri Lanka case – 1 dead, 8 life threatening ADRs • If we would have the same compliance with norms and quality in aircraft industry Globally • approximately 25% planes would not take off the grounds • 10% would crash and kill the people (treatment failure = killing in some cases; toxicity etc. )

  12. Quality can not be assessed, tested or inspected into the product, BUT It has to be built into it!!

  13. Shifting the regulatory paradigm during the history (1) • From elementary quality requirements to safety and efficacy • From quality control of finished product to control of quality of manufacturing (inspection) • From quality control of finished product and inspection of manufacturing sites in general to more understanding the processes and product specific processes involved • From rigid limits to agreed upon beforehand set of limits which can be used by manufacturers in a more flexible manner • …..

  14. Shifting the regulatory paradigm during the history (2) • Increased role of science – new molecules, new advanced therapies and combination therapies (device + medicine, etc) • From national to international – not a single regulator today can work meaningfully in isolation and not using other regulators experience/knowledge/information • Increasing need to decide what regulatory functions to fulfil nationally and what expertise/capacities to build nationally • Increasing need for harmonization, collaboration and cooperation • The future in medicines regulation is in effective collaboration and cooperation

  15. Science and medicines regulation (example): European Medicines Agency (EMA) - First Scientific Workshop On Nanomedicines, 2-3 September 2010, London • Emerging therapies such as nonomedicines give rise to questions on the appropriateness of current regulatory frameworks, the relevance and adequacy of existing requirements and guidelines, and on the availability of adequate expertise to regulators. • Scientific challenges arise from the limitations of current testing methods and the reliability of novel ones, because of the 'nanosize' and the unique behaviour of such nano-systems in biological structures. • Examples of approved nonomedicines: • the anti-neoplastic agent Caelyx includes stealth liposomes of doxorubicinehydrochloride; • the antineoplastic agent Mepact contains mifamurtide in multilamellar liposomes; • the antineoplastic agent Abraxane contains paclitaxel nanoparticles bound to human serum albumin; • the immunosuppressant Rapamune contains sirolimus particles in nanocrystal colloidal dispersion.

  16. Medicines work in WHO HQ – in new Health Systems and Innovation (HIS) cluster. ADG Dr Marie-Paule Kieny • Department of Essential Medicines and Health Products (EMP) • Quality Assurance and Safety: Medicines (QSM) • Collaboration with ROs and COs, other clusters/departments/units and CCs • Regional Offices • Country Offices • Disease oriented programs (HIV/AIDS, TB, Malaria etc.) • Other programs … • WHO Collaborating Centres

  17. What is QSM? Seven technical programmes • Regulatory Support • International Nonproprietary Names (INNs) • Quality Assurance • Anticounterfeiting • Safety (Pharmacovigilance) • Prequalification of Medicines • Quality Assurance and Safety of Blood Products and Related Biologicals

  18. More information: www.who.int/medicines/en/

  19. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/en/index.htmlhttp://www.who.int/medicines/areas/quality_safety/safety_efficacy/en/index.html

  20. Increasing regulatory transparency * * Claire Cornips, Lembit Rägo, Samvel Azatyan, Richard Laing.International Journal of Risk & Safety in Medicine 22 (2010) 77–88

  21. Active collaboration with other international, regional and national organizations • UN family & international organizations: • UNICEF, UNFPA, UNIDO, UNDP etc. • MSF • Regional • Council of Europe/EDQM • EMA/EU • NEPAD • Professional and scientific • FIP, IUPHAR, ISPE • National • NMRAs

  22. WHO collaborating centres (CCs) for medicines • Historically initiated both by regions and the HQ • More regional focus of activities • More Global focus of activities • WHO CCs linked to medicines • Parts of various institutions, mostly universities but also Government institutions including regulators • Independent organizations, units with only CCs objectives • WHO CCs by profiles • CCs linked to overall medicines related topics and not necessarily linked to medicines regulation • Medicines policies & research, rational use of medicines, drug utilization research, assessment for reimbursement & other purposes, pricing etc. • CCs linked to various functional parts of medicines regulation including nomenclatures, classifications and dictionaries • Nomenclatures, dictionaries, methodologies, quality control, pharmacovigilance, research etc.

  23. Nomenclatures and classifications • WHO Collaborating Centre for Drug Statistics Methodology Director / Head:   MScPharm Hanne Strøm; whocc@fhi.noInstitution: Department of Pharmacoepidemiology   Norwegian Institute of Public Health. Address:   Marcus Thranesgt 6, PB 4404 Nydalen  0403, Oslo, Norway. Web Site:   http://www.whocc.no • Terms of Reference: To classify drugs according to the ATC system.  • To establish DDDs for drugs which have been assigned an ATC code.  • To review and revise as necessary the ATC classification system and DDDs.  • To stimulate and influence the practical use of the ATC system by cooperating with researchers in the drug utilization field.  • To organize training courses in the ATC/DDD methodology and to lecture such courses and seminars organized by others.  • To provide technical support to countries in setting up their national medicines classification systems and build capacity in the use of medicines consumption information.

  24. Pharmacovigilance • Title of the centre: WHO Collaborating Centre for International Drug MonitoringDirector / Head: Professor Marie Lindquist, marie.lindquist@who-umc.orgSten.Olsson@who-umc.orgInstitution: The Uppsala Monitoring Centre – known as UMC Address:   Box 1051, S-751 40, Uppsala, Sweden Web Site:   http://www.who-umc.org • Terms of Reference: Collection & processing of data: maintaining & developing the international adverse drug reaction database currently containing 7 million + cases of suspected drug reactions from over 100 countries.  • Data utilization: a) Regular screening of data & distribution of feed-back as determined by the collaborating centres; b) With the help of expert consultants , evaluate new data & produce & distribute "Signal" which alerts on new adverse issues; c) Special database searches on request from both within & outside the Programme. 

  25. Pharmacovigilance • WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance. Director / Head:   Dr Alexander Dodoo  • Institution:   Centre for Tropical Clinical Pharmacology & Therapeutics   University of Ghana Medical School, P. O. Box 4236  GP, Greater Accra • Terms of Reference: Training in pharmacovigilance in African countries for building and strengthening of spontaneous adverse drug reaction reporting systems  • Advocacy for pharmacovigilance across Africa either alone or in collaboration with WHO  • Promoting the integration of pharmacovigilance into public health programmes  • Technical support to national pharnacovigilance centres  • Support in communication and crisis management to national pharmacovigilance centres  • Acquisition (from WHO, UMC) and distribution of needed literature and technical tools to national pharmacovigilance centres and governments  • Research in pharmacovigilance including cohort event monitoring of specified medicines  • Assistance in the development and maintenance of pregnancy registers 

  26. 4.2. Quality control (WPRO, SEARO, AFRO – 4)

  27. 15thICDRA – www.icdra.ee 29 29

More Related